Retatrutidi (GLP-3) miligaramu 40

▎ GLP-3 sigicogo

▎ GLP-3 Sɛgɛsɛgɛli

GLP-3 ɲininiw kɛcogo ye mun ye?

Fasa ni farikoloɲɛnajɛ suguya 2 cayalenba diɲɛ kɔnɔ, o bɛ ka caya ka taa a fɛ, o bɛ gɛlɛyaba lase foroba kɛnɛyako ma. Fura minnu bɛ yen, minnu bɛ kɛ ni laɲini kelen ye walima minnu bɛ kɛ fila ye, dan bɛ olu nafa ni u lakanani na. Ka da hakilina kan min bɛ tali kɛ laɲini caman na minnu bɛ tali kɛ ɲɔgɔn na kɔnɔbara basigilen inisɔndiyalan fɛ, ɲininiw y’a jira ko GLP-1, GIP ani glucagon jɔyɔrɔ bɛ ɲɔgɔn dafa farikoloɲɛnajɛ labɛnni na, o bɛ kɛ sababu ye ka hakilinata jusigilan di walasa ka agoniste caman sɔrɔ minnu bɛ se ka furakɛli kɛ.

Ka da fura dilanni dɔnniya fila kan, ɲininikɛlaw ye GLP-3 labɛn ani k’a ɲɛnabɔ ka ɲɛ ka da nin fura saba minɛbaga ninnu jɔcogo n’u taamasiɲɛw kɛcogo kan. Ni a bɛ GLP-1R, GIPR ani GCGR baara waati kelen na, a bɛ sukarodunbana kunbɛncogo barikama sɔrɔ ani ka girinya dɔgɔya.

GLP-3 ka baarakɛcogo ye mun ye?

Agonisme récepteur (Agonisme récepteur) ye

GLP-3 bɛ baara kɛ i n’a fɔ agoniste saba min bɛ GLP-1, GCGR ani GIP minɛbagaw laɲini ^{[1] .}.

GLP-1 minɛbaga agoniste : GLP-1 ye incretin hormone ye min bɛ bɔ banakɔtaa L selilɛriw fɛ. Ni a sirilen don GLP-1 minɛbagaw la, GLP-3 bɛ inisɔndiya bɔli sabati cogo la min bɛ bɔ sukaro hakɛ la. Sukarodunbana waati la, GLP-3 bɛ siri GLP-1 minɛbagaw la, ka jiginɛ taamasiɲɛw siraw baara minnu bɛ pankreyasi β-cellw bila ka inisɔndiya bɔ ani ka joli sukaro hakɛ dɔgɔya. A bɛ sukaro bɔli fana bali ani ka sugunɛ sukaro bɔli dɔgɔya, o bɛ joli sukaro sabati ka taa a fɛ. GLP-1 minɛbaga agoniste fana bɛ kɔnɔbara lankolonya bila kɔfɛ, ka dɔ fara fasa kan, ka dumuni dunta dɔgɔya, o bɛ dɛmɛ don farikolo girinya kunbɛnni na ^{[2] .}.

GCGR receptor agoniste : A ka ca a la glucagon bɛ baara kɛ sukarodunbana waati la walasa ka joli sukaro hakɛ caya. GLP-3 ka agoniste baara GCGR kan, o ka gɛlɛn. Fasa yɔrɔw la, a bɛ tulumafɛnw bɔli sabati ani ka dɔ fara asidi fatɔw ka oksidan kan, o bɛ fanga musaka caya. Sugunɛ na, GCGR agoniste moyenne bɛ se ka taabolo dɔw ɲɛnabɔ i n’a fɔ gluconeogenesis, ka sugunɛ farikoloɲɛnajɛ baara kɛcogo ɲɛ. O bɛ sukaro camanba bali ka sukarodunbana bila mɔgɔ la ka sɔrɔ ka joli sukaro sabatili sabati walasa ka farikolo fanga ɲininiw dafa ^{[1] .}.

GIP receptor agoniste : GIP, incretin hormone wɛrɛ, o bɛ bɔ K selilɛriw fɛ duodenum ni jejunum kɔnɔ dumuni kɔfɛ. GLP-3 ka GIP minɛbaga agoniste bɛ inisɔndiya bɔli bonya, a ni GLP-1 bɛ baara kɛ ɲɔgɔn fɛ walasa ka sukaro hakɛ labɛncogo ɲɛ. O kɔfɛ, GIP minɛbaga baarakɛli bɛ se ka nɔ bila tulumafɛnw falenni na ani fanga balansi la. Brzozowska P ka ɲininiw y’a jira ko GIP bɛ sukaro tali ni tulumafɛnw sɔrɔli sabati farikolokisɛw la. Nka, GLP-3 ka fanga kɔrɔ, GIP taamasiɲɛw bɛ ladilan walasa ka fanga baaracogo ɲɛ sanni ka tulumafɛnw marali dɔrɔn sabati, o bɛ girinya kunbɛnni ^dɛmɛ.

Jaa 1 GLP-3 ka baarakɛcogo ^{[3] .}.

Fɛnɲɛnɛmafagalanw ka baarakɛcogo bɛɛ lajɛlen

Fanga sukarodunbana kunbɛnni : Ni GLP-3 bɛ fanga sɔrɔyɔrɔ saba minnu kofɔlen don sanfɛ, olu baara, a bɛ fanga sɛnɛcogo ɲɛnabɔ ka ɲɛ. A bɛ farikolojidɛsɛ sabati, ka dɔ fara asidi tuluma doncogo kan mitokondriyaw la walasa ka β-oxydation sɔrɔ ani ka fanga musaka caya. A bɛ dɔ bɔ tulumafɛnw sɔrɔli la ni asidi tuluma tali ni triglycérides sɔrɔli balili ye farikolojidɛsɛbanakisɛw la, o la, a bɛ farikolo fanga marali ni musaka balansi Changer walasa ka girinya dɔgɔyali nɔgɔya. Baganw ka sɛgɛsɛgɛliw la minnu ɲɛsinnen don o ma ani Jastreboff AM ka kɛnɛyako sɛgɛsɛgɛliw la, GLP-3 tali ye dɔ fara fanga musaka hakɛ kan ani ka farikolo tulu dɔgɔya dɔɔni dɔɔni mɔgɔ fasalenw na^hakɛ .

Sukaro sukaro sukarodunbana kunbɛncogo : GLP-3 bɛ joli sukaro hakɛ sɛmɛntiya sira caman fɛ. Inisɔn bɔli lawulili kɔfɛ GLP-1 ni GIP minɛbagaw ka baarakɛcogo fɛ, a bɛ nɔ bila sugunɛ sukaro sɛnɛcogo la ni GCGR labɛnni ye. A bɛ sugunɛbilenni caya kojugu bali, ka sukaro bɔli dɔgɔya, ani ka waati kelen na, a bɛ farikolo yɔrɔw ka sukaro tali ni a baara caya, o la, sukaro hakɛ bɛ to joli la. O nafa ka bon kosɛbɛ banabagatɔ fasalenw ma minnu ka farikoloɲɛnajɛ suguya 2 bɛ u la, ka joli sukaro hakɛ kɔlɔsi ka ɲɛ ani ka sukarodunbana cogoyaw ɲɛ ^{[2] .}.

Sugunɛ ka fɛnɲɛnamafagalanw labɛncogo : Sugunɛ kɔnɔ, GLP-3 tɛ sukaro sɛnɛcogo caman sɛmɛntiya dɔrɔn, nka a bɛ nɔ bila tulumafɛnw sɛnɛcogo fana na. A bɛ dɔ bɔ sugunɛbilenni triglycérides sɔrɔli ni a dalajɛli la, ka sugunɛbilenni ɲɛ, wa a bɛ se ka furakɛli nafa minɛ sugunɛbilenni na min tɛ dɔlɔ ye (NAFLD). Kɛnɛyaso sɛgɛsɛgɛliw la minnu kɛra ni sugunɛbilenni min bɛ sɔrɔ farikoloɲɛnajɛ baarakɛbaliya fɛ (MDAFLD), GLP-3 ye sugunɛ tuluma hakɛ dɔgɔya kosɛbɛ, o b’a jira ko a bɛ nɔ ɲuman bila sugunɛ na^, .

 A bɛ nɔ minnu bila kɔnɔbara basigilen baara la

GLP-3 bɛ kɔnɔbara lankolonya bila kɔfɛ ni GLP-1 sɔrɔyɔrɔw baara ye. Kɔnɔbara lankolonya dɔɔni dɔɔni bɛ dumuni toli waati janya kɔnɔbara la, o bɛ fasa sabatili lase mɔgɔ ma ani ka dumuni dunta kɔfɛta dɔgɔya. O waati kelen na, a bɛ se ka nɔ bila kɔnɔnatumuw ka ɔrimɔni bɔli la ani banakɔtaa lamagacogo la, ka kɔnɔnatumuw ka dumunikɛcogo ni balofɛnw tali kɛcogo ɲɛnabɔ ka taa a fɛ, o la, a bɛ nɔ bɛɛ bila fanga sɔrɔli ni farikolo girinya ^la.

GLP-3 ka agoniste nɔw ni ɲɔgɔn cɛ jɛɲɔgɔnya jumɛn bɛ GLP-1, GCGR ani GIP minɛbagaw kan?

Sineriji fanga sukarodunbana ɲɛnabɔli la

Fanga musaka caya : GCGR baarakɛli bɛ glycogenolyse ni gluconeogenesis sabati walasa ka joli sukaro hakɛ kɔrɔta. A bɛ fanga musaka fana bonya ni tulumafɛnw falenfalenni caya ye ani ka dumuni dunta damatɛmɛ cɛmancɛ fa fɛ. GLP-1R agonistew bɛ inisɔndiya bɔli lawuli ani ka dusukun tangacogo ni farikolo tangacogo kɛ, ka sɔrɔ fana ka fanga dunta dɔgɔya ni kɔnɔbara lankolonya bilali kɔfɛ ani ka dumuni nege bali. Hali ni GIPR baarakɛcogo tulumafɛnw na, o bɛ tulumafɛnw dalajɛli sabati, a cɛmancɛ baara bɛ dumuni dunta dɔgɔya ani ka farikolo girinya nɔgɔya. GLP-3 bɛ nin fɛn saba ninnu laɲini waati kelen na, ka balansi kura sigi fanga sɔrɔli ni musaka cɛ. O bɛ fanga dɔgɔyali sɔrɔ ka ɲɛ, o bɛ kɛ sababu ye ka girinya dɔgɔyali nɔgɔya.

Lipid metabolism labɛnni : GCGR agoniste bɛ lipid metabolism fanga bonya, ka sɔrɔ GIPR baarakɛli farikolo la, o fana bɛ nɔ bila lipid metabolism la. GLP-1R agonistew bɛ se ka nɔ bila farikolojidɛsɛ la cogo la min tɛ ɲɛ, fɛɛrɛw fɛ i n’a fɔ ka inisɔndiya kɛcogo ɲɛ. U ka jɛɲɔgɔnya wale bɛ tulu sɔrɔli, a tiɲɛni ani a tacogo ɲɛnabɔ ka ɲɛ, ka tulu dalajɛli dɔgɔya ani ka farikolo tulu tilatilali ɲɛ. Misali la, sɛgɛsɛgɛli minnu kɛra banabagatɔ fasalenw kan, olu y’a jira ko GLP-3 tali kɔfɛ waati dɔ kɔnɔ, farikolo tuluma kɛmɛsarada la, o bɛ dɔgɔya ani tulumafɛnw hakɛ bɛ ɲɛ fo ka se hakɛ dɔ ma, o b’a jira ko a bɛ se ka kɛ ɲɔgɔn fɛ tulumafɛnw falenfalenni labɛnni ^na.

Sineriji nɔ minnu bɛ sɔrɔ sukaro labɛnni na

Insuline bɔli fanga bonya : GLP-1R agoniste bɛ joli sukaro dɔgɔya ni u sirilen don GLP-1 sɔrɔyɔrɔw la ani ka insuline bɔli sabati. GIP fana bɛ pankreyasi β-cellw lawuli o cogo kelen na walasa u ka inisɔndiya bɔli nɔw bɔ minnu bɛ tali kɛ dumuni dunni na. GLP-3, min bɛ GLP-1R ni GIPR baara waati kelen na, o bɛ inisɔndiya bɔli caya kosɛbɛ, o la, a bɛ joli sukaro hakɛ dɔgɔya ka ɲɛ. Hali ni a ka ca a la GCGR bɛ tali kɛ joli sukaro jiginni na, a nɔw — i n’a fɔ fanga musaka sabatili — bɛ se ka kɛ sababu ye ka sukaro sabatili sabati cogo la min tɛ ɲɛ ni a bɛ baara kɛ ɲɔgɔn fɛ ni a ni a minɛbagaw ye i n’a fɔ GLP-1R. Ka fara o kan, GLP-1 ni GCGR tali faralen ɲɔgɔn kan, o bɛ sukarodunbana farati min bɛ sɔrɔ GCGR fɛ, o kɛlɛ ka ɲɛ, o bɛ kɛ sababu ye ka sukaro hakɛ labɛn ka ɲɛ ani ka ɲɛ.

Glucose Homeostasis (Glucose Homeostasis) labɛnni : Nin farikolojɔlan saba ninnu ka baarakɛɲɔgɔnya bɛ tɛmɛn inisɔn bɔli dɔrɔn kan walasa ka sukaro homeostasis (glucose homeostasis) labɛnni bɛɛ lajɛlen lamini. Ni GLP-3 bɛ nɔ bila sukaro tali la, a baaracogo la, ani a marali la farikolo yɔrɔ caman na i n’a fɔ sugunɛ, farikolojidɛsɛ ani tulumafɛnw, GLP-3 bɛ joli sukaro mara a cogo la min bɛ sabati, o bɛ fɛn caman bali. Nicholls S ka sɛgɛsɛgɛli dɔ la min kɛra farikoloɲɛnajɛ suguya 2 banabagatɔw kan, GLP-3 tali kɛra sababu ye ka dɔ bɔ kosɛbɛ jolisegindumuni hakɛ la, o b’a jira ko a bɛ nɔ ɲuman bila sukarodunbana kunbɛnni kuntaalajan na ani ka a jira ko nin furakɛlifɛn saba ninnu bɛ ɲɔgɔn sɔrɔ sukaro homeostasis labɛnni ^na.

Sinergitiki baarakɛcogo min bɛ kɛ ni taamasiɲɛw cili siraw ye

Siginiden sira min bɛ kɛ tuma caman na: GLP-1R, GCGR ani GIPR bɛ taamasiɲɛ fɔlɔ kɛ G (Gαs) furakisɛw fɛ. Ni GLP-3 bɛ baara kɛ nin minɛbaga saba ninnu kan, a bɛ ɲɔgɔn sɔrɔ walasa ka jiginɛ sira jɛlenw baara i n’a fɔ cAMP-PKA sira. O sira jɛlen baarakɛcogo in bɛ taamasiɲɛw cili baarakɛcogo ɲuman n’a fanga bonya, ka sariyasunba nɔw bonya selilɛriw ka farikoloɲɛnajɛ ni farikolo baarakɛcogo kan.

Sira danfaralenw labɛnni: K’a sɔrɔ u bɛ sira kelenw tila ɲɔgɔn na, a minɛbaga kelen-kelen bɛɛ bɛ taamasiɲɛw rezo kɛrɛnkɛrɛnnenw fana baara. GLP-3 bɛ o sira danfaralenw sɛmɛntiya ɲɔgɔn fɛ, furakɛlikɛlaw ka baarakɛtuma na, o bɛ kɛ sababu ye ka farikoloɲɛnajɛw labɛn ɲɔgɔn fɛ.

Kɔnɔnatumuw ka baarakɛcogo ɲɛnabɔcogo jɛlen

Kɔnɔnatumuw ka ɔrimɔni bɔli nɔ bilali la : GLP-1R agonistew bɛ GLP-1 bɔli lawuli, ka sɔrɔ GIPR agonistew bɛ GIP bɔli ɲɛnabɔ. O kɔnɔnatumuw jɔyɔrɔ ka bon kosɛbɛ kɔnɔbara lamagacogo, dumunikɛcogo ani a minɛcogo caman sɛgɛsɛgɛli la. Ni GLP-3 bɛ a minɛbaga fila bɛɛ baara waati kelen na, a bɛ kɔnɔbara basigilen ɔrimɔni bɔli ɲɛnabɔcogo bɛɛ lajɛlen di, o la, a bɛ nɔ bila kɔnɔbara baara la. A bɛ se ka dɔ bɔ balofɛnw tali teliya la ni a bɛ kɔnɔbara lankolonya hakɛ ni banakɔtaa lamagacogo caman sɛmɛntiya, o bɛ dɛmɛ don ka girinya ni joli sukaro kunbɛn.

Kɔnɔnatumuw ka farikoloɲɛnajɛ lamini ɲɛnabɔli : Ni GLP-3 bɛ kɔnɔbara basigilen ɔrimɔni bɔli labɛn, a bɛ farikoloɲɛnajɛ sigida fana bonya kɔnɔbara basigilen kɔnɔ. A bɛ kɔnɔnatumu nafamaw falenni ni u farikoloɲɛnajɛ sabati ani ka banakɔtaa balilanw baaracogo sɛmɛntiya. O fɛn caman bɛ se ka nɔ bila farikolo ka farikoloɲɛnajɛ bɛɛ lajɛlen na ka taa a fɛ. Ka baara kɛ ɲɔgɔn fɛ ni nɔw ye fanga sɛnɛcogo la ani joli sukaro labɛnni na, o fɛɛrɛw bɛɛ bɛ dɛmɛ don furakɛli nɔw la fasa ni farikoloɲɛnajɛ bana minnu bɛ tali kɛ o la.

GLP-3 baarakɛcogo ye mun ye?

Fasa furakɛli

Kisɛya dɔgɔyali nɔba : Dɔgɔtɔrɔso sɛgɛsɛgɛli caman y’a jira ko GLP-3 bɛ se ka fasa furakɛli kɛ. Fase 2 la, Jastreboff AM ka sɛgɛsɛgɛli fila kɛra, min kɛra ni furakisɛ fila ye, min kɛra ni furakisɛ ye, min kɛra ni baliku 338 ye, lajɛdenw ye GLP-3 ta dɔgɔkun o dɔgɔkun a tata hakɛ caman na walima furakisɛ ta dɔgɔkun 48 kɔnɔ. Jateminɛw y’a jira ko dɔgɔkun 24nan na, miligaramu 1 kulu ye 7,2% dɔgɔya, miligaramu 4 faralen ɲɔgɔn kan kulu ye 12,9% bɔ, miligaramu 8 faralen kulu ye 17,3% bɔ, ani miligaramu 12 faralen kulu ye 17,5% bɔ, ka sɔrɔ furakisɛ ta kulu ye 1,6% dɔrɔn bɔ. Dɔgɔkun 48nan na, miligaramu 1 kulu ye 8,7% dɔgɔya, miligaramu 4 faralen ɲɔgɔn kan kulu ye 17,1% bɔ, miligaramu 8 faralen kulu ye 22,8% bɔ, miligaramu 12 kulu ye 24,2% bɔ, ani furakisɛ ta kulu ye 2,1% bɔ. Lajɛden minnu ye GLP-3 miligaramu 4, miligaramu 8 ani miligaramu 12 ta, olu la, 92%, 100% ani 100% ye u girinya dɔgɔya 5% walima ka tɛmɛ o kan. 75%, 91% ani 93% ye 10% walima ka tɛmɛ o kan. ani 60%, 75% ani 83% ye 15% walima ka tɛmɛ o kan, ni i ye o suma ni 27%, 9% ani 2% ye furakisɛ kulu la. Nin kunnafoniw bɛ GLP-3 nafa jira ka ɲɛ banabagatɔ fasalenw ka girinya dɔgɔyali la ^{[4] .}.

Sukarodunbana suguya 2 furakɛli

Glycémique kɔlɔsili nafa: Lopez DC ni a ɲɔgɔnnaw ka sɛgɛsɛgɛliw. a jira ko GLP-3 bɛ nɔ ɲuman bila sukarodunbana kunbɛnni na farikoloɲɛnajɛ suguya 2 banabagatɔw la. Kɔrɔbɔli dɔ la, min kɛra ni mɔgɔ 353 ye, GLP-3 ye joli segin furakisɛ (HbA1c) dɔgɔya ni 1,64% ye ni i ye a suma ni furakisɛ ta ye. O b’a jira ko GLP-3 ka se ka joli sukaro hakɛ dɔgɔya farikoloɲɛnajɛ suguya 2 banabagatɔw la, o bɛ kɛ sababu ye ka kɛnɛyaso sɔrɔcogo ^ɲɛ.

Nafa min bɛ kɛ ni fɛɛrɛ faralen ye ɲɔgɔn kan : GLP-3 bɛ baara kɛ ni fɛnɲɛnamafagalan caman ye, ka nafa kɛrɛnkɛrɛnnen di furakɛlikɛla kelen ka agonistew kan a ka agoniste fɛɛrɛ faralen fɛ. A tɛ joli sukaro dɔgɔya dɔrɔn ni a bɛ inisɔndiya bɔli lawuli, nka a bɛ inisɔndiya fana bonya, o bɛ farikolokisɛw dɛmɛ u ka inisɔndiya baara ka ɲɛ walasa ka sukarodunbana kunbɛn cogo bɛɛ la. A ka girinya dɔgɔyali nɔ bɛ farikoloɲɛnajɛ cogoya ɲɛ ka taa a fɛ farikoloɲɛnajɛ suguya 2 banabagatɔw la, barisa fasa ye faratiba ye o bana in na ani farikolo girinya dɔgɔyali bɛ joli sukaro kunbɛncogo ɲuman ^nɔgɔya.

Sugunɛbilenni min tɛ dɔlɔ ye, o furakɛli

Sugunɛbilenni hakɛ dɔgɔyali : GLP-3 y’a jira ko a bɛ se ka sugunɛ tulu hakɛ dɔgɔya banabagatɔw la minnu ka sugunɛbilenni bɛ sɔrɔ farikoloɲɛnajɛ baarakɛbaliya fɛ (MDAFLD) ani sugunɛ tuluma hakɛ ≥10%. Kɔrɔbɔli dɔ la, min kɛra ni mɔgɔ fila ye, min kɛra ni furakisɛ ye, mɔgɔ 98 bilala ka GLP-3 (miligaramu 1, miligaramu 4, miligaramu 8, walima miligaramu 12) walima furakisɛ pikiri kɛ dɔgɔkun o dɔgɔkun farikolo jukɔrɔ dɔgɔkun 48 kɔnɔ. Jateminɛw y’a jira ko dɔgɔkun 24nan na, sugunɛbilenni hakɛ caman yeli ni a daminɛ na, o kɛra -42,9% ye miligaramu 1 ta kulu la, -57,0% ye miligaramu 4 ta kulu la, -81,4% ye miligaramu 8 ta kulu la, ani -82,4% ye miligaramu 12 ta kulu la, ni i ye o suma ni +0,3% ye furakisɛ ta kulu la. Nin sɔrɔlen ninnu b’a jira ko GLP-3 bɛ sugunɛbilenni hakɛ dɔgɔya kosɛbɛ, o b’a jira ko furakɛli nafa bɛ se ka kɛ sugunɛbilenni na min tɛ dɔlɔ ye ^{[8] .}.

Sugunɛbilenni baarakɛcogo ɲɛnabɔli : GLP-3 bɛ sugunɛ farikoloɲɛnajɛ baara ɲɛ ka kɛɲɛ ni fanga ni tulumafɛnw sɛnɛcogo ɲɛnabɔ. A bɛ sugunɛbilenni oksidan ni u tiɲɛni sabati, ka tulu dalajɛli dɔgɔya sugunɛ na, ka funu jaabiw ni oksidan degun hakɛw sɛmɛntiya sugunɛ kɔnɔ, ani ka nɔ dɔ bila NAFLD taabolo la, o bɛ banabagatɔw ka sugunɛ kɛnɛya lakana.

Kuncɛli

I n’a fɔ GLP-1R/GIPR/GCGR ka agoniste saba minɛbaga, GLP-3 bɛ farikoloɲɛnajɛ ɲɛnabɔli nɔw kɛ ni jɛ-ka-baara fɛɛrɛ ye min bɛ kɛ ni laɲini caman ye. A nɔw bɛ GLP-1R baara la walasa ka dumuni nege bali ani ka kɔnɔbara lankolonya bila kɔfɛ, o la fanga sɔrɔli bɛ dɔgɔya; GIPR baara walasa ka inisɔndiya bɔli caya ani ka inisɔndiya kɛcogo ɲɛ; ani ka GCGR baara walasa ka tulumafɛnw bɔli ni fanga musakaw sabati ka sɔrɔ ka sugunɛbilenni ni tulumafɛnw sɛnɛcogo ɲɛnabɔ walasa ka tulumafɛnw dalajɛli dɔgɔya. Nin jɛɲɔgɔnya saba in bɛ nɔ bɛɛ lajɛlen sɔrɔ i n’a fɔ sukarodunbana kunbɛnni barikama, farikolo girinya dɔgɔyali kosɛbɛ, ani tulumafɛnw ni sugunɛ tulumafɛnw sɛnɛcogo ɲɛnabɔli. A nafa jɔnjɔn bɛ fasa furakɛli la, ka se ka girinya dɔgɔyali sɔrɔ min bɛ bɔ a tata hakɛ la ni dɔgɔkun 48 kɔnɔ, a bɛ se ka kɛ 24,2% ye. Ni farikolojɔli suguya 2 bɛ a la, a bɛ joli segin furakisɛw dɔgɔya ka ɲɛ ani ka sukarodunbana sɔrɔcogo ɲɛ. Sugunɛbilenni min bɛ sɔrɔ farikoloɲɛnajɛ baarakɛbaliya fɛ, a bɛ sugunɛ tuluma hakɛ dɔgɔya kosɛbɛ, o bɛ nafa caman jira farikoloɲɛnajɛ bana caman na.

A sɛbɛnbaga ko la

Fɛn minnu kofɔlen dòn san fɛ, olu bɛɛ ɲinini Kɛra, k’u Labɛn ani k’u Lajɛ Cocer Peptides fɛ.

Dɔnniya gafe sɛbɛnbaga

Arun J. Sanyal ye sugunɛbilennikɛla ye ani ɲininikɛla min ka baara ɲɛsinnen bɛ sugunɛbanaw ma, kɛrɛnkɛrɛnnenya la sugunɛbilenni min tɛ dɔlɔ ye (NAFLD) ani sugunɛbilenni min tɛ dɔlɔ ye (NASH). A ni Virginia Commonwealth Iniwɛrisite ka furakɛli kalanso jɛra, a kɛra karamɔgɔ ye yen kabini san 1989. Sanyal ye sɛbɛn 1000 ɲɔgɔn sɛbɛn gafe ɲɛnamaw kɔnɔ i n’a fɔ Cell Diabetes, Nature Medicine, The New England Journal of Medicine, ani The Lancet. A ka baara fɔra siɲɛ 104.000 ni kɔ, o b’a jira ko a ye nɔba bila sugunɛbilenni siratigɛ la. A bɛ to ka wari sɔrɔ jamana ka kɛnɛyako baaradaw fɛ kabini san 1995, wa a ye NIH ka dɛmɛ naani minnu bɛ baara la, olu sɛgɛsɛgɛlikɛla kuntigiba ye. Sanyal fana ye bonya sɔrɔ a ka ɲɛmɔgɔya la kɛnɛyaso ɲininiw na ani a ka dɛmɛ kosɔn sugunɛbana furakɛli fɛɛrɛw labɛnni na. Arun J. Sanyal tɔgɔ sɛbɛnnen bɛ citation (citation) kɔnɔ [5].

▎ Sɛbɛn minnu bɛ tali kɛ o la

[1] Brzozowska P, Frańczuk A, Nowinńska B, Makłowicz A, Palacz KA, Lenartowicz I. GLP-3 - GLP agoniste min labɛnna kɔsa in na, o ye fɛn caman tigɛli ye - sɛbɛnw lajɛ. Jogoɲumanya in Spor 2024. Kalanjɛ ni sɛbɛnni: kalanjɛ ni sɛbɛnni gafew.

[2] Doggrell S. A. ye baara kɛ. GLP-3 min bɛ layidu jira fasa la (ani farikoloɲɛnajɛ suguya 2). Dɔnnibaaw ka hakilina Sɛgɛsɛgɛli furaw kan san 2023; 32(11): 997-1001.DOI: 10.1080/13543784.2023.2283020. Kalanjɛ ni sɛbɛnni: kalanjɛ ni sɛbɛnni gafew.

[3] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. GLP-3—Tulonkɛfɛn min bɛ fɛn caman Changer fasa furakɛli la. Biyomolekuli 2025; 15(6).DOI: 10.3390/biom15060796. Ɲɛgɛnɛsiraw ani mɔgɔ dogoyɔrɔw.

[4] Jastreboff A. M., Kaplan L. M., Frías J. P., ani a ɲɔgɔnnaw. Triple-Hormone-Receptor Agonist GLP-3 ka ɲɛsin fasa ma - Fasa 2 sɛgɛsɛgɛli. Angletɛri kura ka furakɛli gafe 2023; 389(6): 514-526. Ɲɛjirali dɔw. DOI:10.1056/NEJMoa2301972. Kalanjɛ ni sɛbɛnni: kalanjɛ ni sɛbɛnni gafew.

[5] Sanyal A. J., Kaplan L. M., Frias J. P., ani mɔgɔ wɛrɛw. Hormone récepteur triple GLP-3 ka ɲɛsin farikolojɔli baarakɛbaliya ma sugunɛbana fɛ: sɛgɛsɛgɛli min kɛra fasa 2a la, min kɛra k’a sɔrɔ a ma kɛ cogo si la. Sigida furakɛli 2024; 30: 2037-2048 sànw. Kalanjɛ ni sɛbɛnni: kalanjɛ ni sɛbɛnni gafew.

[6] Nicholls S, Pirro V, Lin Y, ani a ɲɔgɔnnaw. Triple-hormone receptor agonist GLP-3 bɛ lipoprotéines ni apolipoprotéines (apolipoprotéines) cogoya ɲɛ kosɛbɛ mɔgɔ minnu ka fasa walima minnu girinya ka ca. Erɔpu dusukunnakow gafe 2024; 45(Furakɛcogo_1): ehae666-ehae1501.DOI:10.1093/eurheartj/ehae666.1501.

[7] Lopez D. C., Pajimna J. T., Milan M. D., ani a ɲɔgɔnnaw. 7792 GLP-3 nafa ka bon farikolo girinya dɔgɔyali la ani a dusukun ni farikoloɲɛnajɛ nɔw balikuw la: Seginkanni sigilen ni a sɛgɛsɛgɛli. Journal de la Société endocrine 2024; 8(Furakɛcogo_1): bvae163-bvae749.DOI: 10,1210/jendso/bvae163,749.

[8] Naeem M, Imran L, Banatwala U. GLP-3 fanga bɔli: Se sɔrɔli bɛ se ka kɛ fasa ni girinya tɛmɛnen kan: Sɛbɛnni. Kɛnɛyako dɔnniyaw ka kunnafoniw san 2024; 7(2): e1864.DOI: 10.1002/hsr2.1864. Kalanjɛ ni sɛbɛnni: kalanjɛ ni sɛbɛnni gafew.

BƐƐRƐ KUNNAFONIW NI FƐRƐW KUNNAFONIW BƐƐ MIN BƐ NI WEBSITE KAN NA, olu BƐ KUNNAFONIW FƆLƆ DƆRƆN NI KALANSENW YE.  

Fɛn minnu bɛ di nin siti in kan, olu dabɔra ɲininiw dɔrɔn kama in vitro. Sɛgɛsɛgɛli in vitro (latinkan na: *glasi kɔnɔ*, o kɔrɔ ye gilasi kɔnɔ) bɛ kɛ hadamaden farikolo kɔkan. Nin fura ninnu tɛ furaw ye, Ameriki ka dumuniko ni furako ɲɛmɔgɔso (FDA) ma sɔn u ma, wa u man kan ka kɛ ka furakɛli bana, bana walima bana si bali, k’a furakɛ, walima k’a furakɛ. A dagalen don kosɛbɛ sariya fɛ ka nin fɛn ninnu don hadamaden walima bagan farikolo la cogo o cogo.